Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDAH1 | O94760 | 4/20 | 0.73 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.50 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.50 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16363209 | 0.95 | DDAH1 (0.76) | DDAH1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1343529 | 0.80 | DDAH1 (0.53) | DDAH1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1345585 | 0.74 | DDAH1 (0.48) | DDAH1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL5684996 | 0.71 | GRIN2D (0.76) | DDAH1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1345153 | 0.71 | DDAH1 (0.52) | DDAH1NOS1 | |
| SCHEMBL1345420 | 0.71 | DDAH1 (0.47) | DDAH1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1345473 | 0.69 | DDAH1 (0.44) | DDAH1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL31515411 | 0.69 | DDAH1 (0.55) | DDAH1GRIN2DGRIN3BGRIN1GRIN2A | |
| Hydrochloric Acid SCHEMBL7477733 | 0.69 | DDAH1 (0.42) | DDAH1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL14058759 | 0.68 | DDAH1 (0.42) | DDAH1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828109-B1 | GUANIDINE DERIVATIVES AS INHIBITORS OF DDAH | UCL BUSINESS PLC (GB) | 2013-06-05 | — | — | EP | disclosed |
| US-8063104-B2 | Guanidine derivatives as inhibitors of DDAH | UCL BUSINESS PLC (GB) | 2011-11-22 | — | — | US | disclosed |
| US-20090069331-A1 | GUANIDINE DERIVATIVES AS INHIBITORS OF DDAH | UCL Biomedica PLC c/o Finance Division University College of London (GB) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069331-A1 | GUANIDINE DERIVATIVES AS INHIBITORS OF DDAH | DDAH1, DOHH, IMPDH1 | DDAH1 1/4885GRIN2D 2900/4885GRIN3B 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.